SEC Form 4 · accession 0001193125-26-285505
Dyne Therapeutics, Inc. · DYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erick Lucera
Officer — Chief Financial Officer
Period of report
Jun 25, 2026
Accepted (ET)
Jun 26, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001818794
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 25, 2026 | S | 2,362 | $20.37 | D | 121,563 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- F3Includes 110,513 unvested RSUs.